Биологическая активность
Cariprazine, also known as RGH-188 and MP-214, is an antipsychotic препарат received FDA approval on September 17, 2015. Cariprazine acts as a D2 and D3 рецептор partial агонист, with high selectivity towards the D3 рецептор. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder. Cariprazine is approved for schizophrenia and bipolar disorder. It has also been investigated as a potential adjunct in treatment-resistant major depressive disorder.
Оригинал на английском
Cariprazine, also known as RGH-188 and MP-214, is an antipsychotic drug received FDA approval on September 17, 2015. Cariprazine acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder. Cariprazine is approved for schizophrenia and bipolar disorder. It has also been investigated as a potential adjunct in treatment-resistant major depressive disorder.
Химические свойства
- CAS №
- 1083076-69-0
- Брутто-формула
- C₂₁H₃₃Cl₃N₄O
- Мол. масса
- 463.87 г/моль
- Синонимы
- RGH-188; RGH188; RGH 188; MP-214; MP 214 и ещё 2
Безопасность и документация
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.